China county-based prostate specific antigen screening for prostate cancer and a cost-effective analysis

作者：Zhiguo Zhang, Guoshu Liang, Peng Zhang, Zhongqi Zhao, Zhongnan He, Fengzhen Luo, Zhenqing Chen, Zongke Yang, Zhijie Zhang, Tao Xia, Xin Liu, Yong Zhang, Ye Wei · 发表于：Translational Andrology and Urology · 年份：2021 · DOI：10.21037/tau-21-779 · 被引用次数：14 · 研究领域：Prostate Cancer Diagnosis and Treatment、Prostate Cancer Treatment and Research、AI in cancer detection

BACKGROUND: Prostate cancer is one of the most common malignant tumors worldwide, and is the third-leading cause of cancer death in men. Nearly 70% of new prostate cancer patients in China are locally advanced or widely metastatic with poor prognosis. Providing active treatment to early stage prostate cancer patients can improve the prognosis of prostate cancer patients. Thus, this study sought to evaluate the economy of early prostate specific antigen (PSA) screening for high-risk prostate cancer. METHODS: Based on the data collected from the PSA screening activities of 11 county hospitals from October 2019 to April 2021, this study evaluated a high-risk prostate cancer population who received PSA screening and their quality of life and economy. The screening population comprised males aged over 50 years. All screening patients were tested for PSA. If the PSA value is unnormal, a further diagnosis based on magnetic resonance imagining (MRI) or a transrectal ultrasound-guided prostate biopsy were performed. The decision-tree and Markov model was used to simulate the process of disease development of high-risk prostate cancer patients who underwent screenings and those who did not, and the incremental cost-effectiveness ratio was also evaluated. RESULTS: A total of 13,726 men received a PSA screening. Of these, 1,062 men had abnormal PSA values, and 73 of these were diagnosed with prostate cancer. Of these 73 patients, 40, 21, and 12 had early stage, mid-stage, and late-stage ...